Table 1.
Distribution of demographic and clinical factors among women (n=56) and men (n=43) undergoing IVF
| Factors | Women | Men |
|---|---|---|
| Age, years (mean + SD)a | 38.1 ± 3.34 | 39.6 ± 4.29 |
| BMI (kg/m2)b | 24.0 ± 4.59 | - |
| Race, n (%) | ||
| Asian | 16 (28.6) | 10 (23.3) |
| Other | 40 (71.4) | 26 (60.5) |
| Missing | - | 7 (16.3) |
| Ever smoking, n (%) | ||
| Yes | 11 (19.6) | 1 (2.3) |
| No | 45 (80.4) | 42 (97.7) |
| Diagnosis, n (%) | ||
| DOR | 20 (35.7) | - |
| Unexplained | 16 (28.6) | - |
| Malec | 7 (12.5) | 10 (23.3) |
| Tubal | 5 (8.93) | - |
| Other | 5 (8.93) | - |
| PCOS | 3 (5.36) | - |
| Missing | - | 1 (2.3) |
| Treatment, n (%)d | ||
| Gonadotropin antagonist protocols | 39 (69.6) | - |
| Lupron down-regulated protocols | 12 (21.4) | - |
| Flare protocols | 3 (5.36) | - |
| Missing | 2 (3.57) | - |
| Outcomes, n (%) | ||
| Pregnant | 17 (30.4) | - |
| Live birth | 12 (21.4) | - |
n=1 missing man;
n=4 missing women;
includes 7 couples without a primary female factor infertility diagnosis and 10 couples with a primary or secondary male factor infertility diagnosis;
Gonadotropin antagonist protocols include IVF antagonist (n=21), IVF E2-priming antagonist (n=14), NEP antagonist (n=3), and IVF antagonist-LP start (n=1); Lupron down-regulated protocols include IVF long luteal (n=2) and IVF demi-halt (no OCP) (n=10); Flare protocols include Aygestin priming CC flare antagonist (n=1), IVF Clomid flare-FSH/HMG (n=1), and Clomid only (n=1).
Abbreviations: BMI, body mass index; CC, Clomiphene Citrate; DOR, diminished ovarian reserve; E2, estradiol; FSH, follicle stimulating hormone; HMG, human menopausal gonadotrophin; IVF, in vitro fertilization; LP, luteal phase; NEP, neutral endopeptidase; OCP, oral contraceptives; PCOS, polycystic ovary syndrome